Compare BOTJ & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOTJ | VRCA |
|---|---|---|
| Founded | 1998 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.0M | 107.5M |
| IPO Year | 2015 | 2018 |
| Metric | BOTJ | VRCA |
|---|---|---|
| Price | $27.01 | $5.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | ★ 25.8K | 25.1K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.92% | N/A |
| EPS Growth | ★ 13.71 | N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | $4,273,000.00 | ★ $35,577,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $94.44 |
| P/E Ratio | $44.15 | ★ N/A |
| Revenue Growth | 6.74 | ★ 370.22 |
| 52 Week Low | $13.38 | $3.28 |
| 52 Week High | $27.54 | $9.82 |
| Indicator | BOTJ | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 74.13 | 41.63 |
| Support Level | $22.46 | $5.32 |
| Resistance Level | $27.42 | $6.53 |
| Average True Range (ATR) | 0.62 | 0.40 |
| MACD | 0.02 | -0.08 |
| Stochastic Oscillator | 80.86 | 17.23 |
Bank of the James Financial Group Inc is a bank holding company that provides retail and commercial banking, deposit services, lending services, mortgage brokerage services, and other banking services. The company provides a range of deposit services including checking accounts, savings accounts and other time deposits of various types, ranging from daily money market accounts to longer-term certificates of deposit. It offers various types of secured and unsecured consumer loans, including personal loans, lines of credit, overdraft lines of credit, automobile loans, installment loans, demand loans, and home equity loans. It operates three business segments community banking; mortgage banking, and investment advisory services.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.